Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s stock price traded up 1.8% during mid-day trading on Tuesday. The stock traded as high as $1.1550 and last traded at $1.11. Approximately 310,863 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 1,521,488 shares. The stock had previously closed at $1.09.
Qualigen Therapeutics Stock Performance
The firm has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $1.13. The company has a market capitalization of $2.81 million, a PE ratio of -0.22 and a beta of 0.24.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s research programs are centered on small-molecule and other targeted therapeutic approaches intended to address biological mechanisms associated with tumor growth and disease progression.
Qualigen’s development pipeline has included QN-302, an investigational small-molecule therapy being studied for potential use in oncology, including pancreatic cancer.
Recommended Stories
- Five stocks we like better than Qualigen Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
